- Home
- TLSA vs ADAG Comparison
TLSA vs ADAG Comparison
Compare TLSA & ADAG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TLSA
- ADAG
- Stock Information
- Founded
- TLSA 2013
- ADAG 2011
- Country
- TLSA United Kingdom
- ADAG China
- Employees
- TLSA N/A
- ADAG N/A
- Industry
- TLSA Biotechnology: Pharmaceutical Preparations
- ADAG Biotechnology: Pharmaceutical Preparations
- Sector
- TLSA Health Care
- ADAG Health Care
- Exchange
- TLSA Nasdaq
- ADAG Nasdaq
- Market Cap
- TLSA 187.0M
- ADAG 91.4M
- IPO Year
- TLSA 2000
- ADAG 2021
- Fundamental
- Price
- TLSA $1.53
- ADAG $1.95
- Analyst Decision
- TLSA
- ADAG Strong Buy
- Analyst Count
- TLSA 0
- ADAG 1
- Target Price
- TLSA N/A
- ADAG $8.00
- AVG Volume (30 Days)
- TLSA 253.5K
- ADAG 87.7K
- Earning Date
- TLSA 07-15-2025
- ADAG 07-24-2025
- Dividend Yield
- TLSA N/A
- ADAG N/A
- EPS Growth
- TLSA N/A
- ADAG N/A
- EPS
- TLSA N/A
- ADAG N/A
- Revenue
- TLSA N/A
- ADAG $103,204.00
- Revenue This Year
- TLSA N/A
- ADAG $6,488.89
- Revenue Next Year
- TLSA N/A
- ADAG $57.50
- P/E Ratio
- TLSA N/A
- ADAG N/A
- Revenue Growth
- TLSA N/A
- ADAG N/A
- 52 Week Low
- TLSA $0.63
- ADAG $1.33
- 52 Week High
- TLSA $1.91
- ADAG $3.58
- Technical
- Relative Strength Index (RSI)
- TLSA 50.27
- ADAG 53.92
- Support Level
- TLSA $1.53
- ADAG $1.74
- Resistance Level
- TLSA $1.81
- ADAG $1.99
- Average True Range (ATR)
- TLSA 0.10
- ADAG 0.11
- MACD
- TLSA -0.02
- ADAG -0.01
- Stochastic Oscillator
- TLSA 6.67
- ADAG 58.33
About TLSA Tiziana Life Sciences Ltd.
Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and neuroinflammatory diseases. Its clinical pipeline includes drug assets for Secondary Progressive Multiple Sclerosis, ALS. Alzheimer's, Crohn's Disease, and KRAS+ NSCLC. Tiziana is led by a team of qualified executives with extensive drug development and commercialization experience.
About ADAG Adagene Inc.
Adagene Inc is a platform-driven, clinical-stage biopharmaceutical company engaged in transforming the discovery and development of novel antibody-based cancer immunotherapies. It is principally engaged in research, development, and production of monoclonal antibody drugs for cancers. The company's platform is designed to generate therapeutic antibody candidates with functional epitopes and species cross-reactivity, as highlighted by the company's immunotherapy pipeline.